NCT06927960 - Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions

Androgenetic Alopecia

Interventions

DRUG

AH-001 or placebo

SAD: Subjects are planned to receive a single dose of AH-001 or placebo once MAD: Subjects are planned to receive a single daily dose of AH-001 or placebo for 7 consecutive days

Trial Locations (1)

90630

RECRUITING

Altasciences Clinical Los Angeles, Inc., Los Angeles